Gilead's 2026 Outlook Falls Short of Wall Street Expectations, Stock Price Drops
Gilead Sciences released its 2026 financial forecast on Tuesday, which was at the lower end of analysts' expectations, including sales of its groundbreaking twice-yearly injectable HIV prevention drug, causing its stock price to fall by nearly 2%.
The California-based biotechnology company also reported fourth-quarter 2025 sales and profits that slightly exceeded Wall Street expectations. Quarterly sales of Yeztugo, the twice-yearly injectable HIV prevention drug launched in the U.S. last year, totaled $96 million, surpassing Wall Street's forecast of $88 million. Gilead stated it expects Yeztugo sales to reach $800 million in 2026, while analysts had predicted $907 million. Brian Abrahams, an analyst at RBC Capital Markets, said Yeztugo's forecast is "below investors' 'whisper' expectation of $1 billion." The drug has been shown in clinical trials to be nearly 100% effective in preventing HIV, offering new hope for blocking the virus that infects 1.3 million people globally each year. However, some are hesitant about Yeztugo's U.S. launch price of about $28,000 per year. Gilead said that so far, 90% of U.S. payers have agreed to cover the drug. Gilead also said it expects adjusted earnings per share in 2026 to be between $8.45 and $8.85. Analysts had anticipated earnings per share of $8.75, $0.10 higher than Gilead’s forecast midpoint. Gilead’s stock fell 3% in regular trading and dropped about 2% after hours, closing at $144.52.
Editor: Wang Yongsheng
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel CEO: CPU only meets 50% of demand, 14A to start production in Q1 next year, new architecture may reduce inference power consumption to 1/15 of GPU
Intel CEO Pat Gelsinger stated that the era of AI agents has triggered an explosion in CPU demand, and Intel is currently able to meet only about 50% of its customers' supply needs, with several tech giant CEOs calling to secure supply. In terms of manufacturing process, the 18A node is now in full mass production, while the 14A node will begin production in the first quarter of next year. By opening up factory data, yield rates are improving by about 7% annually. Additionally, he is advancing neuromorphic computing to address energy consumption bottlenecks and expects quantum computing to have a substantial industrial impact within 3 to 5 years.
Reportedly, the US urges Japan to "increase" defense spending; Tokyo considers a 3.5% GDP target, bond market and yen come under pressure first
Under pressure from the United States, Japan is considering setting a new medium-term defense spending target, planning to increase its defense expenditure to 3.5% of GDP to align with NATO and other U.S. allies.
The logic of "cheap yen financing" is changing! Funds are reallocating "carry trades" as Swiss franc and Swedish krona compete for the funding currency position
The appeal of yen financing has diminished, and carry traders have recently turned their attention to the franc and the krona. With the yen’s recent surge making it a less reliable investment option, currencies such as the Swedish krona and Swiss franc are becoming primary funding choices for carry trades.
Crypto prices
More
